Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $1 | $4 | $12 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$4 | -$11 | -$0 |
| Revenue | $0 | $1 | $19 | $1 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Gross Profit | $0 | $1 | $18 | $0 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| EBITDA | -$0 | $0 | $18 | $0 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |
| Net Income | -$0 | $0 | $8 | $0 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| % Growth | -206% | -98.7% | 7,556.7% | – |
| Operating Cash Flow | $0 | -$1 | $15 | $0 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$0 | -$1 | $15 | $0 |